Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 90 member A22 (FAM90A22) is annotated as a protein-coding gene and also as a pseudogene in some resources. Its primary aliases include FAM90A22P and other variations referencing its pseudogene status. It does not encode a well-characterized receptor, enzyme, or classic therapeutic target. Its potential paralog is FAM90A24. As a pseudogene, FAM90A22 may be transcribed and, like some pseudogenes, could possibly generate RNA or peptide products, but there is no current evidence supporting a defined biological function, disease association, or targeting by drugs. FAM90A22 is not considered a validated or established therapeutic target. FAM90A22 is primarily characterized as a pseudogene, and often annotated as "putative protein". There is no robust evidence supporting a role as a receptor, enzyme, transporter, or canonical target class. No data supports clinical targeting, biomarker utility, or disease role. This entry is best described as a pseudogene or putative protein, not a validated molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 90 member A22 (FAM90A22).